Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis
Background/Aims. It remains unclear whether tenofovir disoproxil fumarate- (TDF-) based combination therapy produces better outcomes than TDF monotherapy in chronic hepatitis B (CHB) patients. The aim of this study was to compare the efficacy of the two regimens by performing a meta-analysis. Method...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/7214020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552436744585216 |
|---|---|
| author | Ling Chen Xiwei Wang Qiongfang Zhang Jiaojiao Gong Shasha Shen Wenwei Yin Huaidong Hu |
| author_facet | Ling Chen Xiwei Wang Qiongfang Zhang Jiaojiao Gong Shasha Shen Wenwei Yin Huaidong Hu |
| author_sort | Ling Chen |
| collection | DOAJ |
| description | Background/Aims. It remains unclear whether tenofovir disoproxil fumarate- (TDF-) based combination therapy produces better outcomes than TDF monotherapy in chronic hepatitis B (CHB) patients. The aim of this study was to compare the efficacy of the two regimens by performing a meta-analysis. Methods. A comprehensive literature search was performed on the comparison of TDF-based combination therapy and monotherapy for CHB patients in the PubMed, Embase, Web of Science, and the Cochrane Libraries. Both dichotomous and continuous variables were extracted and pooled outcomes were expressed as risk ratio (RR) or standard mean difference (SMD). Results. Nine eligible studies (1089 subjects in total) were included in our analysis. The proportion of patients with undetectable HBV DNA at 24, 48, and 96 weeks were similar between the two comparable groups (62.5% versus 70.9%, P=0.086; 78.1% versus 83.7%, P=0.118; 86.4% versus 87.9%, P=0.626, resp.). HBV DNA reduction, rates of ALT normalization, hepatitis B e antigen (HBeAg) loss, and HBeAg seroconversion were also similar between the two groups. Conclusions. On the current data, TDF-based combination therapy seemed to be no better than those achieved by monotherapy. Further studies are needed to verify this comparison. |
| format | Article |
| id | doaj-art-65e1504719b240c7a421fc4d6a49d747 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-65e1504719b240c7a421fc4d6a49d7472025-02-03T05:58:36ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/72140207214020Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-AnalysisLing Chen0Xiwei Wang1Qiongfang Zhang2Jiaojiao Gong3Shasha Shen4Wenwei Yin5Huaidong Hu6Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaBackground/Aims. It remains unclear whether tenofovir disoproxil fumarate- (TDF-) based combination therapy produces better outcomes than TDF monotherapy in chronic hepatitis B (CHB) patients. The aim of this study was to compare the efficacy of the two regimens by performing a meta-analysis. Methods. A comprehensive literature search was performed on the comparison of TDF-based combination therapy and monotherapy for CHB patients in the PubMed, Embase, Web of Science, and the Cochrane Libraries. Both dichotomous and continuous variables were extracted and pooled outcomes were expressed as risk ratio (RR) or standard mean difference (SMD). Results. Nine eligible studies (1089 subjects in total) were included in our analysis. The proportion of patients with undetectable HBV DNA at 24, 48, and 96 weeks were similar between the two comparable groups (62.5% versus 70.9%, P=0.086; 78.1% versus 83.7%, P=0.118; 86.4% versus 87.9%, P=0.626, resp.). HBV DNA reduction, rates of ALT normalization, hepatitis B e antigen (HBeAg) loss, and HBeAg seroconversion were also similar between the two groups. Conclusions. On the current data, TDF-based combination therapy seemed to be no better than those achieved by monotherapy. Further studies are needed to verify this comparison.http://dx.doi.org/10.1155/2016/7214020 |
| spellingShingle | Ling Chen Xiwei Wang Qiongfang Zhang Jiaojiao Gong Shasha Shen Wenwei Yin Huaidong Hu Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis Gastroenterology Research and Practice |
| title | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| title_full | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| title_fullStr | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| title_full_unstemmed | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| title_short | Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis |
| title_sort | efficacy of tenofovir based combination therapy versus tenofovir monotherapy in chronic hepatitis b patients presenting with suboptimal responses to pretreatment a meta analysis |
| url | http://dx.doi.org/10.1155/2016/7214020 |
| work_keys_str_mv | AT lingchen efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT xiweiwang efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT qiongfangzhang efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT jiaojiaogong efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT shashashen efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT wenweiyin efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis AT huaidonghu efficacyoftenofovirbasedcombinationtherapyversustenofovirmonotherapyinchronichepatitisbpatientspresentingwithsuboptimalresponsestopretreatmentametaanalysis |